Lead sponsor
Imperial College London
8 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
8
Trials led
3
Active
707
Total enrollment
7
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Early Phase 1
1
Phase 2
3
Not applicable
4
Trials by status
Not yet recruiting
1
Recruiting
2
Completed
2
Withdrawn
1
Unknown
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced DiabetesBMI ≥22.5not applicableRecruiting60